Meeting
2021 ASCO Annual Meeting
A comprehensive landscape of BRCA1 versus BRCA2 associated molecular alterations and survival outcome across 35 cancer types.
Authors
Alberto Puccini
Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
Alberto Puccini , Joanne Xiu , Arielle Lutterman Heeke , Andreas Seeber , Richard M. Goldberg , Wafik S. El-Deiry , Stephen V Liu , Sarah Sammons , Emil Lou , Philip Agop Philip , John Marshall , Anthony Frank Shields , Heinz-Josef Lenz , Thomas J. Herzog , W. Michael Korn , Mohamed E. Salem
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 3120)
DOI
10.1200/JCO.2021.39.15_suppl.3120
Abstract #
3120
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Targeted ctDNA sequencing analysis reveals concurrent genomic alterations and its impact on TKI and immune checkpoint inhibitor therapy in advanced NSCLC from Asian population.
First Author: Wei Wu
Poster
2018 ASCO Annual Meeting
Exploring the association between somatic molecular features and tumor mutation burden in 513 non–small-cell lung cancer.
First Author: Chenchen Zhu
Poster
2016 ASCO Annual Meeting
CHK1 inhibition as a therapeutic approach in KRAS mutated and squamous cell carcinoma NSCLC patients.
First Author: Daniela Morales-Espinosa
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Liquid biopsy-based comprehensive genomic profiling to reveal mutational landscape in real-world patients with gastrointestinal cancer.
First Author: Haoran Tang